Live feed06:00:00·474dPRReleasevia QuantisnowAMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITISByQuantisnow·Wall Street's wire, on your screen.AMGN· Amgen Inc.Health Care